Funding, page-117

Correct as per the Edison report we are well under valued for our current stage on Paxalisib - GDC0084 offering a great risk reward opportunity

And we also know when more results from the second cohort confirm the reported - better than the current standard of care - first cohort results that this stock could have a rather large bump in current values.

Trial results are often the catalysis for meaningful jumps in SP and MC... and many cases support this.

It is great news first reported results show such wonderful
news for both company and patients and that recent gains continue to hold slightly above and slightly below the 60 cent range after a period of some months in the sub 40 cent range

As some have posted we have a rich calendar of news over the next six months.